Last reviewed · How we verify
NCT06076473: PUMPAP
Untargeted Metabolomics for Primary Aldosteronism
trial testing Untargeted metabolomics in Primary Aldosteronism in 40 participants. Status unknown.
19 January 2025
Quick facts
| Lead sponsor | Liverpool University Hospitals NHS Foundation Trust |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 40 |
| Start date | 19 January 2023 |
| Primary completion | 19 January 2025 |
| Estimated completion | 19 January 2025 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- Untargeted metabolomics
Conditions studied
- Primary Aldosteronism — all drugs for Primary Aldosteronism →
Sponsor
Liverpool University Hospitals NHS Foundation Trust
Who can join
Adults 18 to 120, any sex, with Primary Aldosteronism. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Primary aldosteronism (PA) is a common and likely under-diagnosed cause of secondary hypertension with associated cardiovascular morbidity and mortality. Current diagnosis comprises screening, confirmatory testing and sub-type classification (lateralisation) to distinguish unilateral disease (requiring surgery) from bilateral disease (requiring medical management). This multi-step process is complex and variable with a lack of uniformity in diagnostic protocols, standardised/reference assay methodologies, and diagnostic thresholds. There is evidence in the literature that targeted serum steroid panels may have a role in diagnosis of PA, and both targeted steroid panels and untargeted metabolomics in serum and urine are a promising area of research. This study aims to identify and recruit participants (n=40; 20 with confirmed PA and 20 with other causes of hypertension) willing to donate lithium heparin plasma for a metabolomics pilot study. This plasma will be interrogated through untargeted metabolomics using gas/liquid chromatography-mass-spectrometric methods and computational data processing to allow power calculations and inform experimental design for future studies. The utility of metabolites from the metabolomics dataset will be evaluated by comparison against current biomarkers for screening, diagnosis and lateralisation as well as radiology and histology acquired through routine diagnostic work-up. The long-term aim for larger studies is to identify suitable candidate analytes in plasma for future development into targeted, clinically-useful analyte panels.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06076473
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Untargeted metabolomics
Trials testing the same drug.
- NCT06200142 — Zoektocht Naar Erfelijke MetaBole Aandoening (Dutch)/ Solve The Unsolved (English) · NA · completed
Other recruiting trials for Primary Aldosteronism
Currently open trials in the same condition.
- NCT07298954 — Sequential Combined Versus Single-Strategy Adrenal Venous Sampling for Primary Aldosteronism(SCOPE) · NA · recruiting
- NCT07111351 — Multi-omics Studies of Primary Aldosteronism · recruiting
- NCT07027254 — PETAL Trial: Impact of Gallium-68 Pentixafor PET-CT on Surgical Outcomes in Primary Aldosteronism · NA · recruiting
- NCT06941116 — Steroids-Based Screening for Primary Aldosteronism · recruiting
- NCT06955286 — Study on the Incidence of Adrenal Insufficiency After Surgery in Primary Aldosteronism Patients Concurrent With or Witho · recruiting
Other Liverpool University Hospitals NHS Foundation Trust trials
Trials by the same sponsor.
- NCT07391553 — Achilles Tendon Rupture Patient Outcomes at 12 Months · not yet recruiting
- NCT07034469 — Air Tamponade Versus Fluorinated Gas Tamponade for Rhegmatogenous Retinal Detachment · NA · not yet recruiting
- NCT06566638 — Safety, Tolerability and Performance of the NucleoCapture Extracorporeal Therapeutic Apheresis Device in the Reduction o · NA · not yet recruiting
- NCT06600620 — Intelligent Monitoring to Predict Atrial Fibrillation · suspended
- NCT06271031 — Process Mapping and Data Collection to Inform a Computer Simulation Model of Hospitalised Patients With Bloodstream Infe · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06076473 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Liverpool University Hospitals NHS Foundation Trust
- Last refreshed: 15 February 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06076473.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing